Triamcinolone Acetonide Ointment Recalled Due to cGMP Deviations
Teligent Pharma is recalling Triamcinolone Acetonide Ointment USP 0.1% nationwide because the manufacturer is discontinuing its stability study program, creating a current Good Manufacturing Practice (cGMP) deviation.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall. The source text identifies cGMP deviations based on discontinuation of the stability study program, which is a regulatory/documentation issue rather than a reported safety incident. No illnesses, injuries, or specific product quality failures are reported in the source, making this a precautionary, compliance-based recall.
Plain-English summary
Teligent Pharma, Inc. is recalling Triamcinolone Acetonide Ointment USP, 0.1% in all dosage forms: 15-gram tubes (NDC 52565-014-15), 80-gram tubes (NDC 52565-014-80), and 1-pound jars (NDC 52565-014-26). A total of 482,003 tubes and 45,583 jars are affected. The product is distributed nationwide in the USA and Puerto Rico.
The recall is due to current Good Manufacturing Practice (cGMP) deviations. The firm is discontinuing its stability study program, which is required to ensure the product maintains its safety and efficacy throughout its shelf life.
Consumers who have this product should stop using it and consult with their pharmacist or healthcare provider. Patients should not stop taking their prescribed corticosteroid medication without medical guidance; they should contact their healthcare provider for alternative treatment options.
Specific batch numbers and expiration dates affected by this recall are listed in the FDA notice.
The recalled product
- Product
- Triamcinolone Acetonide Ointment USP, 0.1%, packaged in a) 15 grams tubes, NDC 52565-014-15; b) 80 grams tubes, NDC 52565-014-80; c) 1 lb (454 g) jars, NDC 52565-014-26; Rx only, Teligent Pharma, Inc., Buena, New Jersey 08310.
- Manufacturer
- Teligent Pharma, Inc.
- Category
- Drug — Topical Corticosteroid
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Batch: a) 15000
- Exp. 1/31/2023
- 15591
- Exp. 4/30/2023
- 15946
- Exp. 9/30/2023
- b) 14674
- Exp. 11/30/2022
- 14760
- 14798
- Exp. 12/31/2022
- 14896
- 15000
- 15802
- 15833
- Exp. 7/31/2023
- 15872
- Exp. 8/31/2023
- 16069
- Exp. 10/31/2023
Distribution
Part of a larger recall action
This product is one of 37 recalled by Teligent Pharma, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 37 products in this recall →Related recalls
Same manufacturer · Teligent Pharma, Inc.
See all →- ModerateLidocaine Ointment USP 5% Recalled Due to cGMP Deviations
FDA (Drugs) · 2022-03-30
- ModerateDesonide Ointment Recalled Due to cGMP Deviations
FDA (Drugs) · 2022-03-30
- HighDiflorasone Diacetate Ointment recalled due to discontinued stability studies
FDA (Drugs) · 2022-03-30
- ModerateDesoximetasone Ointment USP Recalled by Teligent Pharma
FDA (Drugs) · 2022-03-30
- ModerateClobetasol Propionate Cream USP 0.05% Recall for cGMP Deviations
FDA (Drugs) · 2022-03-30
Same hazard · cgmp deviation
See all →- SevereBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Vancomycin Injection Due to CGMP Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09